A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).
Publication/Presentation Date
5-2014
Volume
32
Issue
15
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS